IPP Bureau
DG, ICMR and Director CSIR-NIScPR release special issues of Vigyan Pragati & Science Reporter magazines
By IPP Bureau - April 13, 2023
Science communication brings behavioural changes
India’s Covid success story hailed the world over as a role model in Crisis Management, says Dr. Singh
By IPP Bureau - April 13, 2023
India's strategy against Covid was more effective than any other countries in the world
LifeSigns introduces ‘Continuum Care’ for Patients
By IPP Bureau - April 13, 2023
Enabling wireless monitoring In ambulances and homes
ProBioGen and ImmunOs Therapeutics join hands to deliver innovative therapy for cancer patients
By IPP Bureau - April 13, 2023
ProBioGen previously developed the cell line and the manufacturing process and provided the initial clinical material for ImmunOs' innovative biologic.
Mandaviya inaugurates Robotic Surgery and AI Department at Yashoda Hospital, Ghaziabad
By IPP Bureau - April 12, 2023
The session took place in the presence of Union Ministers Hardeep Singh Puri and Gen V K Singh along with Anil Agarwal, Rajya Sabha Member of Parliament
Zydus receives final approval from USFDA for Tavaborole Topical Solution
By IPP Bureau - April 12, 2023
Tavaborole Topical Solution, 5% had annual sales of US $3.1 million in the United States
LyGenesis and Imagine Pharma to jointly develop cell therapies for Patients with Type 1 diabetes
By IPP Bureau - April 12, 2023
Collaboration will enable rapid advancement of a joint preclinical proof of concept program for type 1 diabetes
CiRA, Kyoto University and Astellas Phase 2 research agreement signed for iPS Cells
By IPP Bureau - April 12, 2023
CiRA, Kyoto University and Astellas - Second Phase Joint Research Agreement Signed for Medical Applications of iPS Cells
Zydus receives final approval from the USFDA for Azithromycin Tablets
By IPP Bureau - April 11, 2023
Azithromycin Tablets USP, 500 mg had annual sales of US $20 million in the United States
Cipla signs agreement with Novartis for diabetes therapy Galvus range
By IPP Bureau - April 11, 2023
Galvus has the potential to contribute significantly to Cipla’s portfolio in the diabetes care continuum space with reported sales of Rs. 268 crore
Calibre Chemicals takes over R&D activities of Tina Life Sciences
By IPP Bureau - April 11, 2023
Calibre will enhance the pace of new product development and the breadth of its Custom Development and Manufacturing (CDMO) Service offerings.
Shilpa Medicare receives USFDA approval for Psoriatic Arthritis Drug
By IPP Bureau - April 11, 2023
Apremilast Tablets, 10 mg, 20 mg, and 30 mg is a generic equivalent of reference listed drug (RLD) OTEZLA of Celgene.
Mandaviya visits RML, reviews mock drill for ensuring COVID readiness
By IPP Bureau - April 11, 2023
Urges everyone to follow COVID Appropriate Behaviour and curb any misinformation
Astec LifeSciences launches Rs. 100 crore Adi Godrej Center for Chemical Research and Development
By IPP Bureau - April 11, 2023
To enable company to be future-ready by tapping potential in CDMO space
